Navigation Links
Frost & Sullivan Lauds BioTrove for Providing Research-Enabling Life Sciences and Drug Discovery Technologies

MOUNTAIN VIEW, Calif., March 10 /PRNewswire/ -- Frost & Sullivan recognizes BioTrove, Inc. with the 2009 North American Frost & Sullivan Award for Growth Strategy Leadership of the Year. The annual award is based on an analysis of the most significant drug-discovery innovations and acknowledgments by life sciences category leaders. BioTrove, a privately held company specializing in drug acceleration and pipeline assessment technologies, has gained significant traction within biopharmaceutical company and research institution sectors.


The OpenArray(R) technology enables researchers to perform large-volume nanoliter arrays, conducting up to 3,000 assays simultaneously, while the RapidFire(R) Mass Spectrometry (RF-MS) technology uses microfluidics to conduct sample analysis 10-to-100 times faster than conventional liquid chromatography-mass spectrometry (LC-MS) technologies.

"These solid technologies facilitate faster, higher-throughput and ultimately more efficient research and drug discovery," said Frost & Sullivan Research Analyst Christi Bird. "In addition to directly distributing these products to end-users, BioTrove has also collaborated with several top life sciences tool and services providers to develop optimized products, services and workflows utilizing OpenArray(R) or RapidFire(R) technologies."

Collaborations with sector leaders such as Applied Biosystems, Agilent Technologies, BD Biosciences, Gene Express, MDS Analytical Technologies and Synchron Lab Automation have yielded optimized genotyping systems, end-to-end high-throughput mass spectrometry solutions, sample preparation and data analysis of high-throughput in vitro ADME assays, lead discovery and lead optimization services, and even a genetic profiling test for lung cancer risk. This successful business strategy enabled BioTrove to expand its own customer base and brand reputation, increasing distribution channels for RapidFire(R) and OpenArray(R) and expanding business.

"BioTrove has been proactive in partnering with scientists and clinicians to enable higher-throughput research leading to advances in healthcare," added Bird. "The company is a blueprint for sound business strategy and demonstrates that quality and a collaborative spirit remain essential characteristics for successful life sciences companies."

In the past year, BioTrove partnered with OSI Pharmaceuticals, the BloodCenter of Wisconsin, and Constellation Pharmaceuticals to assist research efforts with the company's innovative technologies. These research endeavors ranged from lead compound discovery to single nucleotide polymorphism (SNP) genotyping on the OpenArray(R) system to investigating novel therapeutic targets with the RF-MS system. Researchers often appreciate a company that takes interest in research endeavors and provides value-added support to its customers. Ultimately, BioTrove has demonstrated its commitment to enabling research efforts to advance healthcare through strategic customer partnerships.

For exhibiting best practices in growth strategy, BioTrove is an ideal recipient of the Frost & Sullivan 2009 North American Drug Discovery Technologies Growth Strategy Leadership of the Year Award. Each year, Frost & Sullivan presents this award to the company that has demonstrated an exceptional growth strategy within the industry.

Frost & Sullivan's Best Practices Awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research in order to identify best practices in the industry.

About BioTrove

BioTrove, Inc. offers two innovative technology platforms: OpenArray(R), which advances genomic research in a wide range of life science fields, including agriculture, disease research, and public health, and RapidFire(R), which enables the acceleration of drug discovery and pipeline decisions. With 11 of the 15 largest biopharmaceutical companies based on global sales as clients, and partnerships with prestigious research and public health centers around the world, BioTrove's products and services ensure that an industry committed to accuracy and speed can meet business goals.

The OpenArray(R) Platform enables genomics researchers to generate SNP and real time qPCR data in the hundreds of thousands of data points per day, significantly increasing the number of samples analyzed while significantly decreasing the time and cost required. The flexible format and nanoliter scale of the OpenArray system allows for easy adjustment of sample and assay numbers, achieving economical, high-throughput genomics. Life Technologies globally markets the OpenArray SNP genotyping platform under the TaqMan(R) OpenArray(R) SNP Genotyping brand. BioTrove is a licensee of Life Technologies global patent rights related to the real-time thermal cyclers, microfluidics and data analysis.

RapidFire(R) Mass Spectrometry (RF-MS) feeds samples directly to the mass spectrometer at six to eight seconds per sample, eliminating the bottleneck created by traditional mass spectrometry throughput. RF-MS is routinely used in many applications including the high-throughput screening of previously intractable drug targets, ADME assays and directed evolution studies.

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, enables clients to accelerate growth and achieve best in class positions in growth, innovation and leadership. The company's Growth Partnership Service provides the CEO and the CEO's Growth Team with disciplined research and best practice models to drive the generation, evaluation and implementation of powerful growth strategies. Frost & Sullivan leverages over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from 31 offices on six continents. To join our Growth Partnership, please visit

    Jake Wengroff

SOURCE Frost & Sullivan
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Transport Pharmaceuticals Receives Coveted Frost & Sullivan Technology Innovation Award
2. Nonin Medical, Inc. Receives Frost & Sullivans 2007 Award for Product Differentiation Innovation
3. Digirad Corporation to Receive Frost & Sullivan 2007 North American Award for Product Strategy
4. Signalife Wins Second Frost & Sullivan Technology Award
5. AdvanDx Receives Frost & Sullivans Rapid In-Vitro Diagnostic Technology Innovation of the Year Award
6. Modigene Announces Closing of $12 Million Financing by Members of The Frost Group
7. WuXi PharmaTech (NYSE: WX) Wins the 2008 Frost & Sullivan Award for Best in Class Outsourced R&D in Pharmaceuticals and Biotechnology
8. Exiqon Receives the 2008 Frost & Sullivan Growth Strategy Leadership Award
9. Athera Biotechnology Founder Johan Frostegard and His Colleagues Win NACB Distinguished Abstract Award at AACC 2008
10. Vascular Biogenics Ltd. Presented With the Frost & Sullivan 2008 European Gene Expression Targeting Platform Technology Innovation Award
11. Frost & Sullivan Recognizes Kionixs Dominance in the MEMS Accelerometers Market Through Product Line Strategy
Post Your Comments:
(Date:11/27/2015)... Nov. 27, 2015 /PRNewswire/--  Mallinckrodt plc (NYSE: ... that it has closed the sale of its global ... (GBT- NYSE Euronext) in a transaction valued at approximately ... facilities and a total of approximately 1,000 employees spread ... St. Louis area. This entire workforce ...
(Date:11/27/2015)... PUNE, India , November 27, 2015 ... --> Growing popularity of companion ... emerging in cancer biomarkers market with pharmaceutical ... develop in-demand companion diagnostic tests. ... --> Complete report on global ...
(Date:11/26/2015)... November 26, 2015 --> ... specializing in imaging technologies, announced today that it has received ... of the Horizon 2020 European Union Framework Programme for Research ... clinical trial in breast cancer. , --> ... --> --> The study aims ...
(Date:11/25/2015)...  PharmAthene, Inc. (NYSE MKT: PIP) announced  today that ... plan (Rights Plan) in an effort to preserve the ... Section 382 of the Internal Revenue Code (Code). ... of its NOLs could be substantially limited if the ... 382 of the Code. In general, an ownership change ...
Breaking Biology Technology:
(Date:10/29/2015)...   MedNet Solutions , an innovative SaaS-based eClinical ... research, is pleased to announce that it has been ... one of only three finalists for a 2015 ... Growing" category. The Tekne Awards honor Minnesota ... innovation and leadership. iMedNet™ eClinical ...
(Date:10/29/2015)... , Oct. 29, 2015 Daon, a ... that it has released a new version of its ... in North America have already ... v4.0 also includes a FIDO UAF certified server ... already preparing to activate FIDO features. These customers include ...
(Date:10/29/2015)... , Oct. 29, 2015  Connected health pioneer, ... the explosion of technology-enabled health and wellness, and the ... book, The Internet of Healthy Things ... or smartphones even existed, Dr. Kvedar, vice president, Connected ... health care delivery, moving care from the hospital or ...
Breaking Biology News(10 mins):